JP2019527537A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527537A5 JP2019527537A5 JP2018564975A JP2018564975A JP2019527537A5 JP 2019527537 A5 JP2019527537 A5 JP 2019527537A5 JP 2018564975 A JP2018564975 A JP 2018564975A JP 2018564975 A JP2018564975 A JP 2018564975A JP 2019527537 A5 JP2019527537 A5 JP 2019527537A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- car
- domain
- polypeptide
- antigen receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 229920001184 polypeptide Polymers 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 125000006850 spacer group Chemical group 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 230000000139 costimulatory effect Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000011664 signaling Effects 0.000 claims 5
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 4
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 4
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 230000003834 intracellular effect Effects 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010034016 Paronychia Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 101800001707 Spacer peptide Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 102000046935 human TNFRSF17 Human genes 0.000 claims 1
- 210000003519 mature b lymphocyte Anatomy 0.000 claims 1
- 210000001806 memory b lymphocyte Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000002536 stromal cell Anatomy 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022106290A JP7646604B2 (ja) | 2016-06-07 | 2022-06-30 | キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ－ｔ細胞 |
| JP2024154170A JP7805409B2 (ja) | 2016-06-07 | 2024-09-06 | キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ－ｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16173401 | 2016-06-07 | ||
| EP16173401.7 | 2016-06-07 | ||
| PCT/EP2017/063862 WO2017211900A1 (en) | 2016-06-07 | 2017-06-07 | Chimeric antigen receptor and car-t cells that bind bcma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022106290A Division JP7646604B2 (ja) | 2016-06-07 | 2022-06-30 | キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ－ｔ細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019527537A JP2019527537A (ja) | 2019-10-03 |
| JP2019527537A5 true JP2019527537A5 (https=) | 2020-06-11 |
Family
ID=56112891
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564975A Pending JP2019527537A (ja) | 2016-06-07 | 2017-06-07 | キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ−ｔ細胞 |
| JP2022106290A Active JP7646604B2 (ja) | 2016-06-07 | 2022-06-30 | キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ－ｔ細胞 |
| JP2024154170A Active JP7805409B2 (ja) | 2016-06-07 | 2024-09-06 | キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ－ｔ細胞 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022106290A Active JP7646604B2 (ja) | 2016-06-07 | 2022-06-30 | キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ－ｔ細胞 |
| JP2024154170A Active JP7805409B2 (ja) | 2016-06-07 | 2024-09-06 | キメラ抗原受容体と、ｂｃｍａに結合するｃａｒ－ｔ細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12048718B2 (https=) |
| EP (2) | EP4737481A2 (https=) |
| JP (3) | JP2019527537A (https=) |
| KR (2) | KR20230042703A (https=) |
| CN (1) | CN109641012A (https=) |
| AU (1) | AU2017276706B2 (https=) |
| CA (1) | CA3026778A1 (https=) |
| SG (2) | SG10202012157QA (https=) |
| WO (1) | WO2017211900A1 (https=) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202012157QA (en) * | 2016-06-07 | 2021-01-28 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
| EP3622092A4 (en) | 2017-05-11 | 2021-06-23 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF |
| MX2019013514A (es) | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| WO2018232195A1 (en) | 2017-06-14 | 2018-12-20 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| US12049643B2 (en) | 2017-07-14 | 2024-07-30 | The Broad Institute, Inc. | Methods and compositions for modulating cytotoxic lymphocyte activity |
| WO2019070755A1 (en) | 2017-10-02 | 2019-04-11 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER |
| EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH |
| WO2019094955A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas |
| EP3674327A4 (en) * | 2018-02-01 | 2021-05-05 | Nanjing Iaso Biotherapeutics Co., Ltd. | BINDING OF CHIMERIC ANTIGEN RECEPTOR (CAR) TO BCMA AND USES THEREOF |
| US11807663B2 (en) * | 2018-02-01 | 2023-11-07 | Innovent Biologics (Suzhou) Co., Ltd. | Fully humanized anti-B cell maturation antigen (BCMA) single-chain antibody and use thereof |
| PT3674328T (pt) * | 2018-02-01 | 2024-03-14 | Innovent Biologics Suzhou Co Ltd | Recetor de antigénio quimérico (car) que se liga a bcma e utilizações do mesmo |
| BR112020016176A2 (pt) * | 2018-02-09 | 2022-02-22 | Immatics Us Inc | Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t |
| CA3177757A1 (en) * | 2018-02-16 | 2019-08-22 | Kite Pharma, Inc. | Modified pluripotent stem cells and methods of making and use |
| WO2019195017A1 (en) * | 2018-04-03 | 2019-10-10 | Promab Biotechnologies, Inc. | Bcma-car-t cells |
| CN116836297A (zh) * | 2018-04-12 | 2023-10-03 | 上海赛比曼生物科技有限公司 | 靶向bcma的嵌合抗原受体及其制法和应用 |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| MX2020012028A (es) | 2018-05-11 | 2021-03-29 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer. |
| GB201807862D0 (en) * | 2018-05-15 | 2018-06-27 | Ucl Business Plc | Chimeric antigen receptor |
| WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
| US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| MD3823665T2 (ro) | 2018-07-19 | 2024-05-31 | Regeneron Pharma | Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| US20210379057A1 (en) | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
| US20220170097A1 (en) | 2018-10-29 | 2022-06-02 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
| WO2020092475A1 (en) * | 2018-10-31 | 2020-05-07 | The Children's Hospital Of Philadelphia | T cells from lymphatic fluid for diagnostic and therapeutic use |
| EP3873937A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
| US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| SMT202400408T1 (it) | 2019-01-16 | 2024-11-15 | Caribou Biosciences Inc | Anticorpo umanizzato bcma e cellule bcma-car-t |
| CN111454358A (zh) * | 2019-01-18 | 2020-07-28 | 四川科伦博泰生物医药股份有限公司 | 一种嵌合抗原受体及其应用 |
| AU2020226401A1 (en) * | 2019-02-18 | 2021-10-14 | Memorial Sloan-Kettering Cancer Center | Combinations of multiple chimeric antigen receptors for immunotherapy |
| US20220154282A1 (en) | 2019-03-12 | 2022-05-19 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
| EP3942023A1 (en) | 2019-03-18 | 2022-01-26 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| CA3132587A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| WO2020193628A1 (en) | 2019-03-25 | 2020-10-01 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Enhancement of cytolytic t-cell activity by inhibiting ebag9 |
| MX2021013359A (es) | 2019-04-30 | 2022-01-31 | Crispr Therapeutics Ag | Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19. |
| EP3733707A1 (en) * | 2019-04-30 | 2020-11-04 | Celyad S.A. | Car t-cells targeting bcma and uses thereof |
| WO2020224605A1 (zh) * | 2019-05-07 | 2020-11-12 | 亘喜生物科技（上海）有限公司 | 靶向bcma的工程化免疫细胞及其用途 |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| WO2020245343A1 (en) * | 2019-06-05 | 2020-12-10 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) | Chimeric autoantibody receptor (caar) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease |
| CN120484131A (zh) * | 2019-07-19 | 2025-08-15 | 费城儿童医院 | 包含磷脂酰肌醇蛋白聚糖2结合结构域的嵌合抗原受体 |
| AU2020325690A1 (en) * | 2019-08-02 | 2022-03-03 | Fundació De Recerca Clinic Barcelona-Institut D’Investigacions Biomèdiques August Pi I Sunyer | CAR T-cells against BCMA for the treatment of Multiple myeloma |
| WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
| US12421557B2 (en) | 2019-08-16 | 2025-09-23 | The Broad Institute, Inc. | Methods for predicting outcomes and treating colorectal cancer using a cell atlas |
| CN114222758A (zh) * | 2019-08-20 | 2022-03-22 | 武汉华大吉诺因生物科技有限公司 | 抗bcma抗体及其在car-t领域中的应用 |
| WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
| EP4032907A4 (en) * | 2019-09-20 | 2023-07-05 | Shanghai Genbase Biotechnology Co., Ltd. | Bcma-targeted antibody and chimeric antigen receptor |
| MX2022003414A (es) * | 2019-09-25 | 2022-04-18 | Fate Therapeutics Inc | Celulas efectoras con multiples objetivos y uso de las mismas. |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| US12394502B2 (en) | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| US12195725B2 (en) | 2019-10-03 | 2025-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity |
| US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
| CN110642953B (zh) * | 2019-10-12 | 2021-09-17 | 华夏源（上海）细胞基因工程股份有限公司 | 一种靶向bcma的t细胞受体融合蛋白和应用 |
| CN110669144B (zh) * | 2019-10-12 | 2021-09-17 | 华夏源（上海）细胞基因工程股份有限公司 | 一种靶向b细胞成熟抗原的嵌合抗原受体及其应用 |
| US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
| US12165747B2 (en) | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| WO2021162394A1 (ko) * | 2020-02-14 | 2021-08-19 | 충북대학교 산학협력단 | B세포 성숙화 항원을 표적으로 하는 키메라 항원 수용체 및 이의 용도 |
| AU2021284401A1 (en) | 2020-06-05 | 2023-01-05 | Eisai R&D Management Co., Ltd. | Anti-BCMA antibody-drug conjugates and methods of use |
| KR102316091B1 (ko) * | 2020-06-17 | 2021-10-25 | 국립암센터 | Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도 |
| CN112048481B (zh) * | 2020-09-09 | 2023-02-10 | 广东昭泰体内生物医药科技有限公司 | 一种靶向cd19的嵌合抗原受体nk细胞及其应用 |
| CN112143707A (zh) * | 2020-09-29 | 2020-12-29 | 广东先康达生物科技有限公司 | 一种治疗自身免疫细胞的免疫细胞及其应用 |
| WO2022116086A1 (en) * | 2020-12-03 | 2022-06-09 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
| US20240245722A1 (en) | 2021-05-25 | 2024-07-25 | Vaxcell-Bio | Monobody-based chimeric antigen receptor and immune cell including same |
| WO2023284875A1 (zh) * | 2021-07-16 | 2023-01-19 | 克莱格医学有限公司 | 嵌合抗原受体 |
| CN115466331B (zh) * | 2021-11-18 | 2023-05-30 | 合源生物科技(天津)有限公司 | 靶向bcma的嵌合抗原受体及其应用 |
| AU2023229697A1 (en) | 2022-03-08 | 2024-09-19 | Vaxcell-Bio Co., Ltd. | Pd-l1-specific chimeric antigen receptor and immune cell comprising same |
| JP2025525937A (ja) | 2022-08-05 | 2025-08-07 | ジュノー セラピューティクス インコーポレイテッド | Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体 |
| KR20250054790A (ko) * | 2022-08-08 | 2025-04-23 | 티크바 알로셀 피티이. 엘티디. | 키메라 항원 수용체 도메인 |
| WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
| WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
| KR20250131823A (ko) | 2023-03-31 | 2025-09-03 | 아벨제타 인크. | Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체 |
| CN119371550A (zh) * | 2023-08-10 | 2025-01-28 | 深圳市三启生物技术有限公司 | 含有gprc5d抗体的嵌合抗原受体及其应用 |
| WO2025059533A1 (en) | 2023-09-13 | 2025-03-20 | The Broad Institute, Inc. | Crispr enzymes and systems |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| WO2025117544A1 (en) | 2023-11-29 | 2025-06-05 | The Broad Institute, Inc. | Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof |
| WO2025160324A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| US20250242018A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| CN118344480A (zh) * | 2024-03-19 | 2024-07-16 | 浙江康佰裕生物科技有限公司 | 靶向bcma的单域抗体、嵌合抗原受体及其应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| ATE466948T1 (de) | 1997-03-11 | 2010-05-15 | Univ Minnesota | Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle |
| AU751647B2 (en) | 1998-05-26 | 2002-08-22 | Innogenetics N.V. | Method for expanding primate B cells selectively in immunocompromised mice and producing large numbers of antigen-specific B lymphocytes for the production of primate monoclonal antibodies |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US8236523B2 (en) | 2004-08-23 | 2012-08-07 | The Johns Hopkins University | Camp reporters and high throughput assays |
| EP2160461B1 (en) | 2007-07-04 | 2012-08-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Hyperactive variants of the transposase protein of the transposon system sleeping beauty |
| NZ591543A (en) * | 2008-09-30 | 2012-11-30 | Abbott Lab | Improved antibody libraries |
| WO2013075027A2 (en) * | 2011-11-17 | 2013-05-23 | Emergent Product Development Seattle, Llc | Anti-sil6xr complex binding domains and methods of use |
| RU2766608C2 (ru) * | 2012-04-11 | 2022-03-15 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
| PL2880170T3 (pl) | 2012-08-02 | 2017-02-28 | F.Hoffmann-La Roche Ag | SPOSÓB WYTWARZANIA ROZPUSZCZALNEGO FcR JAKO FUZJI Fc Z OBOJĘTNYM REGIONEM Fc IMMUNOGLOBULINY I JEGO ZASTOSOWANIA |
| BR122020002986A8 (pt) * | 2012-08-20 | 2023-04-18 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Método e composições para imunoterapia celular |
| WO2014068079A1 (en) | 2012-11-01 | 2014-05-08 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| GB201317929D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| KR20160089390A (ko) * | 2013-12-10 | 2016-07-27 | 에프. 호프만-라 로슈 아게 | 다중-하부단위 구조에 대한 약학적 활성 개체의 표적화 전달을 위한 다중-하부단위 구조의 하부단위의 결합 도메인의 용도 |
| CA2939411A1 (en) * | 2014-02-27 | 2015-09-03 | Ucl Business Plc | Ligand |
| WO2015128509A1 (en) * | 2014-02-28 | 2015-09-03 | Glenmark Pharmaceuticals S.A. | Expression constructs and methods for selecting host cells expressing polypeptides |
| GB201403972D0 (en) * | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| PT3514172T (pt) * | 2014-04-01 | 2020-04-21 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Imunorrecetores específicos de claudina-6 e epítopos de células t |
| US10611837B2 (en) * | 2014-04-10 | 2020-04-07 | Seattle Children's Hospital | Transgene genetic tags and methods of use |
| EP3131927B8 (en) * | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| KR102526945B1 (ko) * | 2014-04-30 | 2023-04-27 | 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 | Ｃｄ269에 대한 인간화 항체 |
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| SG10201913782UA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cll-1 chimeric antigen receptor |
| ES2878449T3 (es) * | 2014-07-24 | 2021-11-18 | 2Seventy Bio Inc | Receptores antigénicos quiméricos de BCMA |
| KR102387122B1 (ko) * | 2014-08-19 | 2022-04-14 | 밀테니 비오텍 비.브이. & 씨오. 케이지 | Ssea4 항원에 특이적인 키메라 항원 수용체 |
| TWI751102B (zh) * | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對ｃｄ１９具專一性之抗體及嵌合抗原受體 |
| BR112017005631A2 (pt) * | 2014-09-19 | 2018-06-26 | City Of Hope | células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2 |
| SG10202012157QA (en) | 2016-06-07 | 2021-01-28 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
-
2017
- 2017-06-07 SG SG10202012157QA patent/SG10202012157QA/en unknown
- 2017-06-07 US US16/307,854 patent/US12048718B2/en active Active
- 2017-06-07 EP EP26161870.6A patent/EP4737481A2/en active Pending
- 2017-06-07 AU AU2017276706A patent/AU2017276706B2/en active Active
- 2017-06-07 CA CA3026778A patent/CA3026778A1/en active Pending
- 2017-06-07 SG SG11201810697QA patent/SG11201810697QA/en unknown
- 2017-06-07 WO PCT/EP2017/063862 patent/WO2017211900A1/en not_active Ceased
- 2017-06-07 EP EP17729846.0A patent/EP3463396B1/en active Active
- 2017-06-07 JP JP2018564975A patent/JP2019527537A/ja active Pending
- 2017-06-07 KR KR1020237003879A patent/KR20230042703A/ko not_active Ceased
- 2017-06-07 CN CN201780035831.4A patent/CN109641012A/zh active Pending
- 2017-06-07 KR KR1020187038249A patent/KR102497013B1/ko active Active
-
2022
- 2022-06-30 JP JP2022106290A patent/JP7646604B2/ja active Active
-
2024
- 2024-05-17 US US18/667,995 patent/US12351640B2/en active Active
- 2024-09-06 JP JP2024154170A patent/JP7805409B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527537A5 (https=) | ||
| AU2020204497B2 (en) | Bispecific binding proteins and uses thereof | |
| US11795209B2 (en) | PVRIG polypeptides and methods of treatment | |
| JP7575100B2 (ja) | 免疫細胞活性化のための二重特異性抗体 | |
| US20260078166A1 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| KR102937285B1 (ko) | 신규 항-pd-l1 항체 | |
| JP6722189B2 (ja) | 単量体Ｆｃドメイン | |
| JP2025081649A (ja) | 多価多重特異性ｏｘ４０結合融合タンパク質 | |
| JP2017537925A5 (https=) | ||
| KR20200110358A (ko) | 항-pd-1 항체 및 치료 방법 | |
| JP2022515223A (ja) | ヒトｐｄ－１に対する二機能性分子 | |
| JP2022506598A5 (https=) | ||
| JP2017537919A5 (https=) | ||
| JP2017522893A5 (https=) | ||
| IL277398B1 (en) | Pd-l1 binding affimers, and uses related thereto | |
| CN107172880A (zh) | 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途 | |
| AU2016370659A1 (en) | Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof | |
| JP2017537629A5 (https=) | ||
| AU2015357463A1 (en) | Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators | |
| JP2017527275A5 (https=) | ||
| JP2020532969A5 (https=) | ||
| JP2022542559A5 (https=) | ||
| JP2022548112A5 (https=) | ||
| JP2024539630A5 (https=) | ||
| JP2021529539A5 (https=) |